Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation

Autor(es)

Martins Fernandes Paes, Barbara Cristina ; Moco, Pablo Diego ; Pereira, Cristiano Goncalves ; Porto, Geciane Silveira ; de Sousa Russo, Elisa Maria ; Junqueira Reis, Luiza Cunha ; Covas, Dimas Tadeu ; Picanco-Castro, Virginia

• Tipo de documento: Artigo de Revisão
• Fonte: CELL BIOLOGY AND TOXICOLOGY; v. 33, n. 3, p. 233-250, MAY 2017.
• Citações Web of Science: 7

Resumo

Ten years have passed since the first publication announcing the generation of induced pluripotent stem cells (iPSCs). Issues related to ethics, immune rejection, and cell availability seemed to be solved following this breakthrough. The development of iPSC technology allows advances in in vitro cell differentiation for cell therapy purpose and other clinical applications. This review provides a perspective on the iPSC potential for cell therapies, particularly for hematological applications. We discuss the advances in in vitro hematopoietic differentiation, the possibilities to employ iPSC in hematology studies, and their potential clinical application in hematologic diseases. The generation of red blood cells and functional T cells and the genome editing technology applied to mutation correction are also covered. We highlight some of the requirements and obstacles to be overcome before translating these cells from research to the clinic, for instance, iPSC variability, genotoxicity, the differentiation process, and engraftment. Also, we evaluate the patent landscape and compile the clinical trials in the field of pluripotent stem cells. Currently, we know much more about iPSC than in 2006, but there are still challenges that must be solved. A greater understanding of molecular mechanisms underlying the generation of hematopoietic stem cells is necessary to produce suitable and transplantable hematopoietic stem progenitor cells from iPSC. (AU)

• Processo FAPESP: 16/08373-9 - Obtenção de eritrócitos a partir de células-tronco de pluripotência induzida em cultivo feeder-free com meio xeno-free
• Beneficiário: Bárbara Cristina Martins Fernandes Paes
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 16/08374-5 - Modificação de linfócitos T com receptor de antígenos quimérico anti-CD19
• Beneficiário: Pablo Diego Moço
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 14/22500-8 - Identificação de tecnologias promissoras no setor da biotecnologia vermelha baseado em análises de patentes
• Beneficiário: Cristiano Gonçalves Pereira
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado